Home » Topics » Regulatory » EMA

EMA
RSS

Abbott voluntarily withdraws E.U. marketing authorization for Trudexa

Aug. 1, 2007

Bausch & Lomb Ireland withdraws Retisert marketing authorization application

July 27, 2007

Rasilez recommended for E.U. approval

June 25, 2007

Orlistat GSK recommended for approval in E.U.

June 1, 2007

Protherics withdraws European application for Voraxaze

May 31, 2007

European CHMP recommends approval of Siklos

May 10, 2007

Pergoveris recommended for E.U. approval

May 9, 2007

Ariad receives FDA feedback on pivotal study of AP-23573 for metastatic sarcoma

April 11, 2007

Lilly withdraws E.U. marketing authorization application for Arxxant

April 10, 2007

EMEA recommends restrictions on use of Ketek

April 4, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...